Difference between revisions of "Abiraterone (Zytiga)"
Jump to navigation
Jump to search
m (zytigaone link) |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.<ref name="insert">[http://www.zytiga.com/downloads/full_product_information.pdf Abiraterone (Zytiga) package insert]</ref><ref>[[Media:Abiraterone.pdf | Abiraterone (Zytiga) package insert (locally hosted backup)]]</ref> | + | Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.<ref name="insert">[http://www.zytiga.com/downloads/full_product_information.pdf Abiraterone (Zytiga) package insert]</ref><ref>[[Media:Abiraterone.pdf | Abiraterone (Zytiga) package insert (locally hosted backup)]]</ref><ref>[http://www.zytiga.com/ Zytiga manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.zytiga.com/downloads/full_product_information.pdf#page= | + | *[http://www.zytiga.com/downloads/full_product_information.pdf#page=8 Abiraterone (Zytiga) package insert PDF pages 8-9]<ref name="insert"></ref> |
| + | *[http://www.chemocare.com/chemotherapy/drug-info/abiraterone-acetate.aspx Abiraterone (Zytiga) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/abiraterone-acetate.aspx Abiraterone (Zytiga) patient drug information (Chemocare)]</ref> | ||
*[http://www.zytigaone.com ZytigaOne patient support resources]<ref>[http://www.zytigaone.com ZytigaOne patient support resources]</ref> | *[http://www.zytigaone.com ZytigaOne patient support resources]<ref>[http://www.zytigaone.com ZytigaOne patient support resources]</ref> | ||
*[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *4/28/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm FDA approved] "to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy)." | ||
| + | *12/10/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm331492.htm FDA approved] "to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy." | ||
| + | |||
| + | ==Also known as== | ||
| + | Abiraterone acetate. | ||
==References== | ==References== | ||
Revision as of 16:24, 14 June 2013
General information
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Abiraterone (Zytiga) package insert PDF pages 8-9[1]
- Abiraterone (Zytiga) patient drug information (Chemocare)[4]
- ZytigaOne patient support resources[5]
- Abiraterone (Zytiga) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/28/2011: FDA approved "to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy)."
- 12/10/2012: FDA approved "to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy."
Also known as
Abiraterone acetate.
References
- ↑ 1.0 1.1 1.2 Abiraterone (Zytiga) package insert
- ↑ Abiraterone (Zytiga) package insert (locally hosted backup)
- ↑ Zytiga manufacturer's website
- ↑ Abiraterone (Zytiga) patient drug information (Chemocare)
- ↑ ZytigaOne patient support resources
- ↑ Abiraterone (Zytiga) patient drug information (UpToDate)